Pathos Revenue, Valuation, Funding & Investors

Insitro is a drug discovery company integrating machine learning with high-throughput biology to identify novel therapeutic targets. South San Francisco-headquartered and founded in 2018, it generates functional genomic datasets from bioengineered cell models aligned with patient clinical data. Insitro's predictive models accelerate small molecule development for diseases like oncology and fibrosis. The company collaborates with pharmaceutical partners on precision medicine programs using its industrial-scale wet lab facilities.

InSilico Medicine Cayman TopCo is engaged in applying artificial intelligence (AI) solutions to drug discovery and development by leveraging its proprietary platforms. It has generated multiple clinical-stage or IND-enabling assets using Pharma.AI, an AI-enabled platform that supports drug discovery and development activities. The company operates under a project-based business model, deriving revenue from out-licensing and collaboration arrangements. Geographically, the company generates revenue from multiple countries, with the majority of the revenue coming from United States.

Gimlet Labs is a San Francisco-based applied research laboratory building scalable AI infrastructure for machine learning workloads. The team develops open-source tools for distributed training, model serving, and data pipelines compatible with frameworks like PyTorch and TensorFlow. Gimlet Labs collaborates with cloud providers such as AWS and Google Cloud to optimize GPU clusters and inference engines for enterprises handling petabyte-scale datasets.

Heyuan Biotechnology is a Chinese provider of gene therapy services, specializing in AAV and lentiviral vector production, CRISPR-based gene editing, and in vivo efficacy testing. Operating from facilities certified under ISO 13485, it supports pharma clients with plasmid design, viral packaging at titers exceeding 10^13 vg/mL, and animal model studies for CNS and oncology targets.

HyperSat LLC is a commercial satellite imagery provider holding a NOAA license for high-resolution hyperspectral data. It delivers analysis for environmental monitoring, agriculture, oil and gas exploration, insurance, mining, law enforcement, disaster recovery, defense, and intelligence applications. The company plans orbital deployments to supply global decision-makers with unique spectral insights distinguishing materials at fine scales.

Parloa is a Berlin-headquartered conversational AI platform automating customer service across voice, chat, and messaging channels. Its AI agents manage inquiries for insurance, retail, and telecom firms, with natural language processing in 20 languages. Deployed by Swiss Life for 24/7 phone support and Decathlon for e-commerce chats, Parloa handles 5 million interactions monthly. Founded in 2017, it complies with DSGVO standards and integrates with CRM systems like SAP and Genesys.

Jilin Aodong Pharmaceutical Group Co Ltd is engaged in manufacturing of pharmaceuticals. Its products include Anshen Bunao Liquid, Antelope Cough Syrup, Yangxue Yin Oral Liquid, Xinnao Shutong Capsule, Calf Spleen Extract Injection, Xuefu Zhuyu Oral Liquid, and others.

Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.

China Medical System Holdings Ltd is active in the healthcare segment. It is one of the China-based pharmaceutical services companies in the country. The company's business mainly involves the marketing, promotion, and sales of prescription pharmaceutical products manufactured by domestic pharmaceutical companies. Some of its products include Plendil, Salofalk, Combizym, and others.

Mianbi Smart is a Chinese AI infrastructure provider optimizing large language model inference and deployment. Its platform accelerates model execution on GPUs through quantization and pruning techniques, supporting frameworks like TensorRT and ONNX. Targeted at enterprises, it reduces latency for applications in natural language processing and generative AI.

Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum of its revenue from the Bausch + Lomb segment.

Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.

Motive is a fleet operations platform headquartered in San Francisco with global reach. The company equips businesses with AI dashcams, GPS tracking, ELDs, and analytics for driver safety and compliance in trucking, field services, and construction. Serving 7 million drivers, Motive automates coaching for behaviors like harsh braking, integrates maintenance workflows, and provides spend controls, boosting efficiency for enterprises like Uber Freight partners.

Sunshine Lake Pharma Co Ltd is a a vertically integrated pharmaceutical company engaging in research and development, production and commercialization of pharmaceutical products. It strategically focus on therapeutic areas of infectious diseases, chronic diseases and oncology. Its existing anti-infective product portfolio mainly includes (i) its top-selling product, Kewei (oseltamivir phosphate), for the treatment of influenza (in particular, Type A and Type B influenza viruses), (ii) one innovative drug developed in-house, Dongweien (emitasvir phosphate), for the treatment of hepatitis C, and (iii) three generic drugs for the treatment of infections caused by sensitive bacteria, namely Clarithromycin, Levofloxacin and Moxifloxacin Hydrochloride.

IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.

Terminus Group is a Beijing-headquartered AIoT provider building smart city infrastructure worldwide. The company deploys AloT platforms integrating surveillance cameras, edge computing, and robotics for urban management in projects across China, Middle East, and Latin America. Listed on Hong Kong Stock Exchange since 2022, Terminus delivers solutions for safe cities, sustainable development, and intelligent transportation systems used by governments in Dubai and Shenzhen.

Arena is an artificial intelligence evaluation platform based in San Francisco, California, founded in 2023. Users submit prompts and compare responses from anonymous AI models side by side, and their votes feed public leaderboards that rank models. The leaderboards cover text generation, coding, image creation, video generation, document analysis and web development. The platform also offers tools to build landing pages, dashboards, games and full-stack apps with AI models. Its community-driven rankings give model developers and users a public benchmark of real-world performance.

NewLimit is a South San Francisco-headquartered biotechnology company advancing epigenetic reprogramming to extend human healthspan. The firm develops therapies restoring cellular function in aging tissues, targeting diseases like neurodegeneration and cardiovascular conditions. NewLimit's platform integrates machine learning with partial reprogramming techniques to identify optimal rejuvenation protocols.